Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01737814 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC)
A Phase 3 study, sponsored by Mast Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 388
- Enrollment target
NCT01737814: Completed Phase 3 study, sponsored by Mast Therapeutics.
NCT01737814 is a Phase 3 study that has completed, run by Mast Therapeutics. The registered enrollment target is 388 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01737814, a Phase 3 study, has completed, sponsored by Mast Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 388 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether MST-188 can reduce the duration of vaso-occlusive crisis (VOC) in subjects with sickle cell disease. The study will also evaluate whether MST-188 can reduce the frequency of rehospitalization of subjects due to a recurrence of VOC. Additionally, this study will compare the development of acute chest syndrome during VOC in subjects who receive MST-188 to those who do not receive MST-188.
Interventions
- DRUG Saline
- DRUG MST-188
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 388 participants |
| Start Date | 2013-05 |
| Phase | Phase 3 |
What the finished NCT01737814 record still lists
NCT01737814 is an interventional study that assigns participants to a tested intervention. The registered 388 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.
NCT01737814 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01737814 about?
NCT01737814 is a clinical study titled "Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC)". The purpose of this study is to evaluate whether MST-188 can reduce the duration of vaso-occlusive crisis (VOC) in subjects with sickle cell disease. The study will also evaluate whether MST-188 can reduce the frequency of rehospitalization of subjects due to a recurrence of VOC. Additionally, this ...
What is the current status of trial NCT01737814?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 388 participants. The study started on 2013-05.
What interventions are being tested in trial NCT01737814?
The interventions under investigation include: Saline (DRUG), MST-188 (DRUG).
Who is sponsoring clinical trial NCT01737814?
This trial is sponsored by Mast Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01737814's enrollment target sits among peer trials
388 973rd of 2000 higher than 1,028 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04092010 · 388 participants · NA
Improving Preschool Outcomes by Addressing Maternal Depression in Head Start
- NCT05157880 · 388 participants · NA
Building Resiliency in Dyads of Patients With an ANI Admitted to the Neuro-ICU and Their Informal Caregivers
- NCT05748613 · 388 participants · NA
Anxiety Sensitivity Treatment to Reduce Anxiety in Alzheimer's
- NCT06374277 · 388 participants · NA
Pharmacy-led Transitions of Care Intervention to Improve Medication Adherence
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia